Cagrilintide
InvestigationalAlso known as: AM833, CagriSema (in combination with semaglutide)
Metabolic & Weight ManagementLast reviewed: April 28, 2026
A long-acting amylin analog developed by Novo Nordisk. Amylin is a hormone co-secreted with insulin that regulates appetite and gastric emptying. Being developed both standalone and in combination with semaglutide (CagriSema) — a combination showing weight loss exceeding 22% in Phase 3 trials, potentially the next step beyond tirzepatide.
Mechanism of Action
Activates amylin receptors (CALCR/RAMP) in the brain, particularly in the area postrema and hypothalamus, reducing appetite through a pathway distinct from GLP-1. The combination with semaglutide targets two separate appetite-regulating systems simultaneously, producing additive weight loss beyond either agent alone.
Common Uses
- Weight management (investigational)
- Type 2 diabetes (investigational)
- Metabolic syndrome
Known Risks
- GI side effects (nausea, vomiting) — similar to GLP-1 class
- Still in Phase 3 trials — full safety profile not established
- Injection site reactions
- Long-term effects unknown
Regulatory Status
Currently in Phase 3 trials as CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg). Phase 3 REDEFINE 1 trial showed ~22.7% weight loss at 68 weeks. Potential FDA submission 2026-2027. Represents the next generation beyond tirzepatide in the weight management pipeline.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection (investigational)
Typical Dose
2.4 mg (in combination trials)
Frequency
Once weekly
Cycle Length
Ongoing — not commercially available
Not available outside clinical trials. The CagriSema combination is the primary development focus. Check clinicaltrials.gov for active REDEFINE trials.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.